JPMorgan downgraded Phreesia (PHR) to Neutral from Overweight with a price target of $16, down from $24. The main takeaway from the Q4 earnings report is the 7% cut to fiscal 2027 revenue guidance, which management attributed to worsening visibility, the analyst tells investors in a research note. The firm now sees better ways to play the health technology space.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHR:
- Phreesia downgraded to Neutral from Outperform at Baird
- Phreesia downgraded to Hold from Buy at Truist
- Phreesia: Solid Operating Leverage but Regulatory Headwinds and Slowing Life Sciences Growth Warrant Hold Rating
- Balanced View on Phreesia: Solid Profitability Gains Offset by Weaker Growth Visibility and Elevated Execution Risk Supporting a Hold Rating
- Balanced View on Phreesia: Solid Profitability and Valuation Support Offset by Growth Uncertainty and Estimate Revisions